Legend Biotech Corp Hits 52-Week Low Amid Market Weakness

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Feb 15 2026

0mins

LEGN+4.51%

Should l Buy LEGN?

Source: NASDAQ.COM

Legend Biotech Corp experienced a significant decline of 7.73%, hitting a 52-week low amidst broader market conditions.

The Nasdaq-100 and S&P 500 indices showed slight gains, indicating a disconnect between Legend Biotech's performance and the overall market trend. This decline may reflect investor concerns regarding the company's recent developments.

As Legend Biotech navigates through this challenging period, market analysts will be closely monitoring upcoming announcements and performance metrics to gauge potential recovery and investor sentiment.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy LEGN?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on LEGN

Wall Street analysts forecast LEGN stock price to rise

11 Analyst Rating

10 Buy

1 Hold

0 Sell

Strong Buy

Current: 18.090

Low

48.00

Averages

68.10

High

90.00

Current: 18.090

Low

48.00

Averages

68.10

High

90.00

RBC Capital

Outperform

maintain

$66 -> $62

2026-03-11

Reason

RBC Capital

Price Target

$66 -> $62

AI Analysis

2026-03-11

maintain

Outperform

Reason

RBC Capital lowered the firm's price target on Legend Biotech to $62 from $66 and keeps an Outperform rating on the shares after its Q4 results. The firm sees a significant disconnect between the share price and the fundamentals of the business, the analyst tells investors in a research note. The management's execution on many aspects of the Carvykti opportunity has been strong, with impressive Overall Survival data, improving real-world safety, expanding manufacturing, and consistent double digit revenue growth, the firm adds.

Morgan Stanley

Overweight

maintain

$50 -> $49

2026-03-11

Reason

Morgan Stanley

Price Target

$50 -> $49

2026-03-11

maintain

Overweight

Reason

Morgan Stanley lowered the firm's price target on Legend Biotech to $49 from $50 and keeps an Overweight rating on the shares. The firm, which updated estimates following the company's Q4 report, awaits additional data from the CARTITUDE-5 study and the earlier-stage in vivo pipeline this year.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LEGN

Unlock Now

About LEGN

Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Legend Biotech (LEGN) Q4 2025 Earnings Transcript

1 hour agoNASDAQ.COM

Legend Biotech (LEGN) Q4 2024 Earnings Transcript

1 hour agoNASDAQ.COM

Legend Biotech (LEGN) Q2 2025 Earnings Transcript

1 hour agoNASDAQ.COM

Legend Biotech (LEGN) Q1 2025 Earnings Transcript

1 hour agoNASDAQ.COM

Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates

6 days agoBarron's

Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.

EEMA Stock Price Fluctuation and ETF Dynamics

Mar 20 2026NASDAQ.COM

Price Range Analysis: EEMA's 52-week low is $63.50 per share, with a high of $107.9984, and the latest trade at $96.12 indicates significant price fluctuations that may influence investor buying decisions.
Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in trend assessment and potential buying opportunities.
ETF Trading Mechanism: Exchange-traded funds (ETFs) operate similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, allowing investors to assess the impact on underlying assets and make informed investment decisions.

Legend Biotech (LEGN) Q4 2025 Earnings Transcript

1 hour agoNASDAQ.COM

Legend Biotech (LEGN) Q4 2024 Earnings Transcript

1 hour agoNASDAQ.COM

Legend Biotech (LEGN) Q2 2025 Earnings Transcript

1 hour agoNASDAQ.COM

Legend Biotech (LEGN) Q1 2025 Earnings Transcript

1 hour agoNASDAQ.COM

Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates

6 days agoBarron's

Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.

EEMA Stock Price Fluctuation and ETF Dynamics

Mar 20 2026NASDAQ.COM

Price Range Analysis: EEMA's 52-week low is $63.50 per share, with a high of $107.9984, and the latest trade at $96.12 indicates significant price fluctuations that may influence investor buying decisions.
Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in trend assessment and potential buying opportunities.
ETF Trading Mechanism: Exchange-traded funds (ETFs) operate similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, allowing investors to assess the impact on underlying assets and make informed investment decisions.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for LEGN?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy LEGN?

Get Started Free